ClinicalTrials.gg
Not yet recruitingNCT07597486Updated May 19, 2026

The Effect of Intraoperative Esketamine Infusion on Pruritus in Elderly Surgical Patients

An interventional study of Esketamine and Normal Saline in Senile Pruritus, sponsored by Tianjin Medical University General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Tianjin Medical University General Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Study summary

To explore the effect of intraoperative esketamine on pruritus in elderly patients undergoing elective general anesthesia for knee replacement surgery

Read the detailed description

Pruritus (itching) is one of the most common clinical conditions in the elderly population. Its etiology is complex, and the prevalence gradually increases with age. Pruritus in the elderly not only imposes a significant disease burden but also severely affects their sleep quality and daily life. This chronic, persistent itching often disrupts the skin barrier function, easily creating a vicious itch-scratch cycle, which leads to multiple damages to the patient's quality of life.Esketamine is the right-handed isomer of ketamine and is a non-competitive N-methyHD-aspartate (NMDA) receptor antagonist. It has the effects of rapid pain relief,rapid antidepressant action, sedation, and improvement of sleep. Relevant studies have shown that the NMDA receptor may play an importantrole in the transmission of non-histaminergic itching. However, there is still a lack of reports on whether it can relieve pruritus symptoms in elderly patients. This experiment intends to investigate the effect of intraoperative esketamine infusion on skin pruritus in elderly surgical patients.

02

Conditions studied

  • Senile Pruritus

Browse trials for

Keywords

  • esketamine
  • pruritus
03

In context

Pruritus

490 studies on the registry are indexed under Pruritus; 93 are open to participants now.

This study's planned enrollment of 200 is above the median of 60 across 422 interventional studies indexed under Pruritus.

Browse Pruritus studies →

Lead sponsor

Tianjin Medical University General Hospital is the lead sponsor of 75 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria for senile pruritus:

    1. Aged ≥ 65 years old;
    2. Presenting with only skin pruritus without obvious primary skin lesions, with or without scratch-induced skin lesions;
    3. Daily or nearly daily pruritus lasting for more than 6 weeks.
  2. Patients undergoing elective general anesthesia for orthopedic knee arthroplasty.
  3. Patients aged ≥ 65 years old, with classification Ⅰ-Ⅲ; ranging from 18 to 30 kg/m², with no restriction on gender.
  4. Patients have fully understood the nature of this study, are capable of understanding and completing evaluation scales preoperatively, voluntarily participate in this trial, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Those who are allergic to the pharmaceutical ingredients of this study or have an allergic constitution;
  2. Those with a history of allergy to general anesthetics, opioids, or non-steroidal anti-inflammatory drugs;
  3. Those with severe cognitive impairment, a history of neurological diseases, chronic pain, drug addiction, alcoholism, long-term opioid use, or administration of opioids within 48 hours before surgery;
  4. Patients with classification Grade IV-V;
  5. Those with severe coronary heart disease/arrhythmia/cardiac insufficiency, bronchial asthma, severe hypertension, severe hematopoietic system dysfunction, severe abnormal liver and kidney function, or significant electrolyte disorders;
  6. Those with a history of gastrointestinal diseases (peptic ulcer, Crohn's disease, ulcerative colitis);
  7. Those with respiratory insufficiency or respiratory failure;
  8. Those with \< 18 kg/m² or BMI > 30 kg/m²;
  9. Those with poor compliance who cannot complete the trial in accordance with the research protocol;
  10. Those who have participated in other clinical drug trials within the past 4 weeks;
  11. Those deemed unsuitable for enrollment by the researchers for any reason. -
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Placebo comparator
    Elderly patients with senile pruritus receive normal saline.

    An equal volume of normal saline is intravenously administered 30 minutes prior to the completion of the operation.

    Drug: Normal Saline

  • Active comparator
    Elderly patients with pruritus receive esketamine at a dose of 0.2 mg/kg.

    Esketamine 0.2 mg/kg is intravenously administered 30 minutes prior to the completion of the operation.

    Drug: Esketamine

Interventions

  • Esketamine 0.2 mg/kg is intravenously administered 30 minutes prior to the completion of the operation.

  • DrugNormal Saline

    An equal volume of normal saline is intravenously administered 30 minutes prior to the completion of the operation.

06

What researchers measure

Primary outcomes

  1. 5D-IS score at 24 hours after surgery

    The duration, severity, outcome trend, life impairment and pruritus site (5-D) were used to evaluate the patient's pruritus.Each dimension was scored from 1 to 5, with a total score ranging from 5 to 25. The higher the score, the more severe the itching.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. 5D-IS score at 48 hours,72 hours and the seventh day after surgery

    The duration, severity, outcome trend, life impairment and pruritus site (5-D) were used to evaluate the patient's pruritus.Each dimension was scored from 1 to 5, with a total score ranging from 5 to 25. The higher the score, the more severe the itching.

    Time frame: 48 hours,72 hours and the seventh day after surgery

  2. The incidence of pruritus on the 24 hours after surgery

    The 5D-IS score was completed by the patient 24 hours after the operation. The investigators recorded this score as a statistical indicator.

    Time frame: 24 hours after surgery

  3. NRS pruritus score at 24 hours,48 hours and 72 hours after surgery

    The patient evaluated the intensiy of prurtus wth 11 numbers ranging from 0 to 10,and the higher the number, the more severe the condition. The higher the number, the more severe the itching. 0: No sensation. 1-3: Mild itching. 4-6 Moderate itching 7-9: Severe itching. 10; Extrermely severe itching.

    Time frame: 24 hours,48 hours and 72 hours after surgery

  4. Pain Score (NRS)

    The pain score at rest or after movement was evaluated by pain 11-point numerical rating scale (NRS): 0= no pain, 10 = greatest imaginable pain.

    Time frame: 1 hours, 24 hours, 48 hours, 72 hours after the surgery

  5. The incidence of postoperative sleep disturbance on the first. second and third postoperative nights

    The patient completed the Sleep Quality Scale (AlS, Athens Insomnia Scale) one day before the surgery, There are a totat of 8 items in the AlS,with the score ranging from 0 to 24. A total score of 6 or above indicates a diagnosis of insomnia. We asked the patients to fill out this questionnaire after the first,second and third postoperative nights to evaluate the changes in sleep quality. The investigators recorded AlS scores as statistical indicators.

    Time frame: the first,second and third nights after surgery

  6. Montreal Cognitive Assessment (MoCA)

    The Montreal Cognitive Assessment consists of 7 items, which evaluate visuospatial and executive function (5 points), naming (3 points), attention (6 points), language (3 points), abstract thinking (2 points), delayed recall (5 points), and orientation (6 points) respectively. A total score of ≥26 points indicates basically normal cognitive function; a total score of \<25 points suggests cognitive decline.

    Time frame: 24 hours, 48 hours, 72 hours after the surgery

  7. Confusion Assessment Method (CAM)

    Confusion Assessment Method CAM is assessed based on four core features. Feature 1: Acute onset or fluctuating course; Feature 2: Inattention; Feature 3: Disorganized thinking; Feature 4: Altered level of consciousness. The diagnosis of delirium requires a positive result for Feature 1 + a positive result for Feature 2 + a positive result for either Feature 3 or Feature 4.

    Time frame: 24 hours, 48 hours, 72 hours after the surgery

Other outcomes

  1. Intraoperative Anesthesia Information

    Duration of anesthesia (minutes)

    Time frame: Perioperative period

  2. Intraoperative Vital Signs

    Intraoperative average heart rate

    Time frame: Perioperative period

  3. Adverse Event

    All kinds of adverse events(nausea, vomiting, respiratory depression, headache, dizziness, chills, delayed recovery from anesthesia) occurred in patients were recorded.

    Time frame: 1 hour, 24 hours, 48 hours and 72 hours after surgery

  4. Intraoperative Anesthesia Information

    Duration of surgery (minutes)

    Time frame: Perioperative period

  5. Intraoperative Anesthesia Information

    Intraoperative dosage of Sufentanil (μg)

    Time frame: Perioperative period

  6. Intraoperative Anesthesia Information

    Intraoperative dosage of Remifentani (mg)

    Time frame: Perioperative period

  7. Intraoperative Vital Signs

    intraoperative average blood oxygen saturation

    Time frame: Perioperative period

  8. Intraoperative Vital Signs

    Mean Arterial Pressure(MAP)

    Time frame: Perioperative period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jun 2027, 13 months later.

Of 85 non-industry interventional studies with no phase under Pruritus, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 13 months is above that.

Counting every sponsor, half of 101 studies reached it within 7 months; a quarter within 3 and three quarters within 13.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 19, 2026
StartEst.
May 15, 2026
Primary completionEst.
Jun 20, 2027
CompletionEst.
Sep 30, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07597486
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Guolin Wang (professor, Tianjin Medical University General Hospital) — Principal investigator
First posted
May 19, 2026
Start date
May 15, 2026 (estimated)
Primary completion
Jun 20, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Guolin Wang
Contact
wangguolinhad@hotmail.com
15822855556
Guolin Wang
study director · Tianjin Medical University General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion